Synopsis
Synopsis
0
CEP/COS
0
KDMF
0
VMF
0
FDF
0
Australia
0
South Africa
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. 7681-82-5
2. Ioduril
3. Sodium Monoiodide
4. Soiodin
5. Iodure De Sodium
6. Sodium Iodide (nai)
7. Sodiumiodide
8. Jodid Sodny
9. Sodium;iodide
10. Mfcd00003532
11. Nsc-77388
12. Iodide (as Sodium Iodide)
13. Fdy-5301
14. F5wr8n145c
15. Chembl1644695
16. Chebi:33167
17. Natriumjodid
18. Natrii Iodidum
19. Sodium Iodide, Ultra Dry
20. Jodid Sodny [czech]
21. Caswell No. 777
22. Natriumjodid [german]
23. Hsdb 750
24. Einecs 231-679-3
25. Nsc 77388
26. Epa Pesticide Chemical Code 075702
27. Sodium Iodide [usp:jan]
28. Unii-f5wr8n145c
29. Sodium-iodide
30. Iodeto De Sodio
31. Ioduro Di Sodio
32. Yoduro De Sodio
33. Sodium Iodide-
34. Sodium Iodide,99%
35. Sodium Iodide Solution
36. Sodium Iodide, Anhydrous
37. Sodium Iodide, Acs Grade
38. Wln: Na I
39. Ec 231-679-3
40. Sodium Iodide [ii]
41. Sodium Iodide [mi]
42. Sodium Iodine-131(1-)
43. Dsstox_cid_21125
44. Dsstox_rid_79629
45. Sodium Iodide [jan]
46. Dsstox_gsid_41125
47. Sodium Iodide [hsdb]
48. Sodium Iodide [inci]
49. Sodium Iodide (jp17/usp)
50. Sodium Iodide [vandf]
51. Sodium Iodide [mart.]
52. Sodium Iodide [who-dd]
53. Dtxsid2041125
54. Sodium Iodide, Trace Metals Grade
55. Bcp22179
56. Nsc77388
57. Tox21_301379
58. Sodium Iodide [ep Monograph]
59. Sodium Iodide [usp Monograph]
60. Akos015950612
61. Akos016015354
62. Db11119
63. Ncgc00255631-01
64. Cas-7681-82-5
65. Iodide (as Sodium Iodide) [vandf]
66. Cs-0013799
67. Ft-0645131
68. S0564
69. D04874
70. Q390305
Molecular Weight | 149.8942 g/mol |
---|---|
Molecular Formula | INa |
Hydrogen Bond Donor Count | 0 |
Hydrogen Bond Acceptor Count | 1 |
Rotatable Bond Count | 0 |
Exact Mass | 149.89424 g/mol |
Monoisotopic Mass | 149.89424 g/mol |
Topological Polar Surface Area | 0 Ų |
Heavy Atom Count | 2 |
Formal Charge | 0 |
Complexity | 2 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
1 of 2 | |
---|---|
Drug Name | Sodium iodide i 123 |
PubMed Health | Sodium Iodide I 123 (By mouth) |
Drug Classes | Diagnostic Agent |
Active Ingredient | Sodium iodide i-123 |
Dosage Form | Capsule |
Route | Oral |
Strength | 100uci; 200uci |
Market Status | Prescription |
Company | Cardinal Hlth 414; Mallinckrodt |
2 of 2 | |
---|---|
Drug Name | Sodium iodide i 123 |
PubMed Health | Sodium Iodide I 123 (By mouth) |
Drug Classes | Diagnostic Agent |
Active Ingredient | Sodium iodide i-123 |
Dosage Form | Capsule |
Route | Oral |
Strength | 100uci; 200uci |
Market Status | Prescription |
Company | Cardinal Hlth 414; Mallinckrodt |
...CAN BE USED INTERCHANGEABLY WITH POTASSIUM IODIDE, AS A THERAPEUTIC AGENT, EXCEPT WHERE SODIUM ION IS CONTRAINDICATED.
Osol, A. and J.E. Hoover, et al. (eds.). Remington's Pharmaceutical Sciences. 15th ed. Easton, Pennsylvania: Mack Publishing Co., 1975., p. 802
VET: HAS BEEN USED FOR RINGWORM, HYPERPLASTIC FIBROUS LESIONS, PARAPLEGIA FROM PACHYMENINGITIS OF DOGS.
The Merck Index. 9th ed. Rahway, New Jersey: Merck & Co., Inc., 1976., p. 1116
VET: ...IT MAY BE USEFUL IV FOR OTHER MYCOSES, CHRONIC JOINT SWELLINGS, LARYNGITIS, BRONCHITIS, & PLEURITIS IN MANY SPECIES; LUNGWORM INFECTIONS IN CATS; TO IMMOBILIZE THALLIUM IN THE BODY; BY CATHETER INTO THE BLADDER AS AN X-RAY CONTRAST MEDIA...
Rossoff, I.S. Handbook of Veterinary Drugs. New York: Springer Publishing Company, 1974., p. 541
DOSE--ORAL, 300 MG TO 2 G DAILY; USUAL, 300 MG 2-4 TIMES A DAY; IV INFUSION, 1-3 G DAILY; USUAL, 1 G.
Osol, A. and J.E. Hoover, et al. (eds.). Remington's Pharmaceutical Sciences. 15th ed. Easton, Pennsylvania: Mack Publishing Co., 1975., p. 802
For more Therapeutic Uses (Complete) data for SODIUM IODIDE (15 total), please visit the HSDB record page.
VET: ...MONITOR IODISM. AVOID UNNECESSARY USE IN ADVANCED PREGNANCY...IT MAY PRODUCE GOITER IN NEWBORN. .../AVOID/ USE OF MILK FROM TREATED ANIMALS FOR AT LEAST 72 HR & 6 MILKINGS AFTER SUCH TREATMENT. MAY POTENTIATE BARBITURATE ANESTHESIA IN RATS.
Rossoff, I.S. Handbook of Veterinary Drugs. New York: Springer Publishing Company, 1974., p. 541
IODIDES MAY PPT THYROTOXICOSIS WHEN GIVEN TO PT WITH NODULAR GOITERS, OR IN EUTHYROID PT WITH AUTONOMOUS THYROID FUNCTION...DURING REMISSION OF HYPERTHYROIDISM FOLLOWING A COURSE OF THIONAMIDES... IN PT WITH CHRONIC THYROIDITIS, PREVIOUS RADIOIODINE THERAPY OR THYROIDECTOMY, IODIDES MAY INDUCE HYPOTHYROIDISM. /IODIDES/
Miller, R. R., and D. J. Greenblatt. Handbook of Drug Therapy. New York: Elsevier North Holland, 1979., p. 918
CONTRAINDICATIONS (VET): HYPERTHYROIDISM & PREGNANCY. WARNING: ANIMALS VARY IN SUSCEPTIBILITY TO IODIDES. ADMIN WITH CAUTION UNTIL TOLERANCE IS DETERMINED. DISCONTINUE TREATMENT IMMEDIATELY IF SYMPTOMS OF IODISM APPEAR... /SODIUM IODIDE 20%/
Aronson, C.E. (ed.). Veterinary Pharmaceuticals & Biologicals, 1980-1981. Media, Pa.: Harwal Publishing Co., 1980., p. 16/30
POTENTIAL ADVERSE EFFECTS ON FETUS: Goiters, fetal encephalopathy. POTENTIAL SIDE EFFECTS ON BREAST-FED INFANT: May cause skin rash and thyroid suppression in infant. FDA Category:D (D = There is no evidence of human fetal risk but the potential benefits from use in pregnant women may be acceptable despite the potential risks (e.g., if the drug is needed in a life-threatening situation or for a serious disease for which safer drugs cannot be used or are ineffective.) /Iodides/ /from table II/
Stockton, D.L. and A.S. Paller. J Am Acad Dermatol 23 (1):87-103 (1990)
3(?). 3= MODERATELY TOXIC: PROBABLE ORAL LETHAL DOSE (HUMAN) 0.5-5 G/KG, BETWEEN 1 OUNCE & 1 PINT (OR 1 LB) FOR 70 KG PERSON (150 LB). /IODIDE SALTS/
Gosselin, R.E., H.C. Hodge, R.P. Smith, and M.N. Gleason. Clinical Toxicology of Commercial Products. 4th ed. Baltimore: Williams and Wilkins, 1976., p. II-78
Indicated for use as a supplement to intravenous solutions given for total parenteral nutrition (TPN).
When intravenously administered for total parental nutrition, sodium iodide prevents the depletion of endogenous stores of iodine and subsequent deficiency symptoms.
Absorption
Iodide salts are readily absorbed in the gastrointestinal tract.
Route of Elimination
Iodides are expected to be renal excreted.
Volume of Distribution
Iodides are distributed widely throughout extracellular fluid of thyroid gland.
RESPONSE TO IODIDE IN HYPERTHYROIDISM: /IN THYROID GLAND/...VASCULARITY IS REDUCED, GLAND BECOMES MUCH FIRMER & EVEN HARD TO THE TOUCH, CELLS BECOME SMALLER, COLLOID REACCUMULATES IN FOLLICLES, & QUANTITY OF BOUND IODINE INCREASES. /IODIDES/
Gilman, A. G., L. S. Goodman, and A. Gilman. (eds.). Goodman and Gilman's The Pharmacological Basis of Therapeutics. 6th ed. New York: Macmillan Publishing Co., Inc. 1980., p. 1412
HIGH CONCN OF IODIDE APPEAR TO INFLUENCE ALL IMPORTANT ASPECTS OF IODINE METABOLISM BY THE THYROID GLAND. CAPACITY OF IODIDE TO LIMIT ITS OWN TRANSPORT... ACUTE INHIBITION OF SYNTHESIS OF IODOTYROSINE & IODOTHYRONINE BY IODIDE IS ALSO WELL KNOWN (THE WOLFF-CHAIKOFF EFFECT)... /IODIDES/
Gilman, A. G., L. S. Goodman, and A. Gilman. (eds.). Goodman and Gilman's The Pharmacological Basis of Therapeutics. 6th ed. New York: Macmillan Publishing Co., Inc. 1980., p. 1413
THIS INHIBITION /WOLFF-CHAIKOFF EFFECT/ IS OBSERVED ONLY ABOVE CRITICAL CONCN OF IODIDE, & THE INTRACELLULAR...CONCN OF ANION APPEARS TO BE MAJOR DETERMINANT. WITH TIME THERE IS "ESCAPE" FOR THIS INHIBITION...ASSOCIATED WITH AN ADAPTIVE DECR IN IODIDE TRANSPORT & LOWERED INTRACELLULAR IODIDE CONCN. /IODIDES/
Gilman, A. G., L. S. Goodman, and A. Gilman. (eds.). Goodman and Gilman's The Pharmacological Basis of Therapeutics. 6th ed. New York: Macmillan Publishing Co., Inc. 1980., p. 1413
THE MOST IMPORTANT CLINICAL EFFECT OF HIGH IODIDE CONCN IS AN INHIBITION OF THE RELEASE OF THYROID HORMONE. THIS ACTION IS RAPID & EFFICACIOUS IN SEVERE THYROTOXICOSIS. THE EFFECT IS EXERTED DIRECTLY ON THE THYROID GLAND, & IT CAN BE DEMONSTRATED IN EUTHYROID SUBJECT & EXPTL ANIMALS AS WELL AS IN HYPERTHYROID PT. /IODIDES/
Gilman, A. G., L. S. Goodman, and A. Gilman. (eds.). Goodman and Gilman's The Pharmacological Basis of Therapeutics. 6th ed. New York: Macmillan Publishing Co., Inc. 1980., p. 1413
IODIDE ANTAGONIZES THE ABILITY OF BOTH THYROTROPIN & CYCLIC AMP TO STIMULATE ENDOCYTOSIS OF COLLOID, PROTEOLYSIS, & HORMONE SECRETION. /REPORTEDLY/... IODIDE ATTENUATES THE EFFECT OF TSH ON CYCLIC AMP IN VIVO & IN ISOLATED TISSUES. /IODIDES/
Gilman, A. G., L. S. Goodman, and A. Gilman. (eds.). Goodman and Gilman's The Pharmacological Basis of Therapeutics. 6th ed. New York: Macmillan Publishing Co., Inc. 1980., p. 1413
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 32132
Submission : 2017-10-12
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 35355
Submission : 2020-12-04
Status : Active
Type : II
GDUFA
DMF Review : Reviewed
Rev. Date : 2020-06-17
Pay. Date : 2020-06-11
DMF Number : 6440
Submission : 1986-06-27
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 23252
Submission : 2009-12-02
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 25853
Submission : 2012-03-23
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 35015
Submission : 2020-08-11
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 18368
Submission : 2005-05-18
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 15227
Submission : 2001-01-03
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 8064
Submission : 1989-05-05
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 23252
Submission : 2009-12-02
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 6738
Submission : 1986-12-22
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 15011
Submission : 2000-08-22
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 8064
Submission : 1989-05-05
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 15227
Submission : 2001-01-03
Status : Inactive
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2020-06-17
Pay. Date : 2020-06-11
DMF Number : 6440
Submission : 1986-06-27
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 18368
Submission : 2005-05-18
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 19885
Submission : 2006-10-20
Status : Inactive
Type : II
USDMF
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 7227
Submission : 1987-11-20
Status : Inactive
Type : II
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
USDMF
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 5574
Submission : 1984-11-01
Status : Inactive
Type : II
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?